CEO Vounatsos, Aduhelm Commercial Team To Exit As Biogen Shifts Focus

More Jobs, Cost Cuts Bring Year’s Total To $1bn

 
• By Mandy Jackson

The company will prioritize later-stage R&D, including potential accelerated approval for a second anti-amyloid antibody, while replacing its CEO and cutting Aduhelm commercial operations and other costs.

A double wooden door chained closed
Biogen is shutting down nearly all Aduhelm commercial operations • Source: Shutterstock

More from Earnings

More from Business